

Has TRISS changed the guidelines?


Bodil Steen Rasmussen
Professor, consultant, PhD
Department of Cardiothoracic Anaesthesia and Intensive
Care

Aalborg University Hospital

Denmark

President-elect EACTA

Conflicts of interest - none





October 2014

ORIGINAL ARTICLE

Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock

Lars B. Holst, M.D., Nicolai Haase, M.D., Ph.D., Jørn Wetterslev, M.D., Ph.D., Jan Wernerman, M.D., Ph.D., Anne B. Guttormsen, M.D., Ph.D., Sari Karlsson, M.D., Ph.D., Pär I. Johansson, M.D., Ph.D., Anders Åneman, M.D., Ph.D., Marianne L. Vang, M.D., Robert Winding, M.D., Lars Nebrich, M.D., Helle L. Nibro, M.D., Ph.D., Bodil S. Rasmussen, M.D., Ph.D., Johnny R.M. Lauridsen, M.D., Jane S. Nielsen, M.D., Anders Oldner, M.D., Ph.D., Ville Pettilä, M.D., Ph.D., Maria B. Cronhjort, M.D., Lasse H. Andersen, M.D., Ulf G. Pedersen M.D., Nanna Reiter, M.D., Jørgen Wiis, M.D., Jonathan O. White, M.D., Lene Russell, M.D., Klaus J. Thornberg, M.D., Peter B. Hjortrup, M.D., Rasmus G. Müller, M.D., Morten H. Møller, M.D., Ph.D., Morten Steensen, M.D., Inga Tjäder, M.D., Ph.D., Kristina Kilsand, R.N., Suzanne Odeberg-Wernerman, M.D., Ph.D., Brit Sjøbø, R.N., Helle Bundgaard, M.D., Ph.D., Maria A. Thyø, M.D., David Lodahl, M.D., Rikke Mærkedahl, M.D., Carsten Albeck, M.D., Dorte Illum, M.D., Mary Kruse, M.D., Per Winkel, M.D., D.M.Sci., and Anders Perner, M.D., Ph.D., for the TRISS Trial Group* and the Scandinavian Critical Care Trials Group

Sepsis versus cardiac surgery

- HAEMODILUTION due to fluid resuscitation
 - Crystalloids
 - Colloids



- C-Reactive Protein
- Leucocytes
- Capillary leakage





TRISS



<u>Transfusion Requirements In Septic Shock</u>

- The Capital Hospital in Denmark
- Scandinavian Critical Care Trials Group



Funded by the Danish Research Council



Transfusion and septic shock

 50% of patients with septic shock receive red blood cells (RBCs)

Perner et al. N Engl J Med 2012

Median 3-5 units of RBCs

Rosland et al. Scand J Trauma Resusc Emerg Med. 2014 Brandstrup et al. LIVES 2014



Is a lower threshold safe?



Risks of anaemia

- Low DO₂
- Ischemia
- Organ dysfunction

Risks of transfusion

- Infectious
- Non-infectious
 - Storage-lesion
 - Immunomodulation

Aims




To assess the **effects and safety** of a lower versus a higher haemoglobin threshold for red blood cell transfusion on **mortality and morbidity** in patients with **septic shock** in the ICU

Design



Multicentre, randomised, partly blinded trial



Primary outcome



Death by 90 days

Secondary outcomes

Use of life support

lschemic events in the ICU

Serious adverse reactions

Days alive and out of hospital



Primary outcome

Death by 90 days

Secondary outcomes

Use of life support

Ischemic events in the ICU

Sample size




2 x 500 patients to show a 9%* absolute difference in death at day 90 from expected 45%, an alpha of 0.05 and a power of 80%


*derived from the 20% RRR in the subgroup of patients with severe infection in TRICC, NEJM 1999

32 Scandinavian ICUs





Trial flow





Exclusions



- 219 Were excluded
 - 3 Had wish against transfusion
 - 4 Had previous adverse reaction to transfusion
 - 137 Had received blood transfusion in ICU
 - 20 Had acute coronary syndrome
 - 16 Had life-threatening bleeding
 - 3 Had acute burn injury
 - 17 Withdrew from active therapy
 - 34 Were excluded because consent could not be obtained

Baseline characteristics

	Lower n = 503	Higher —— n=497
Age	67 (57-73)	67 (58-75)
Emergency surgery	38%	44%
Chronic cardiovascular disease	15%	13%
Haematological malignancy	8%	7%
SAPS II score	51 (42-62)	52 (44-64)
SOFA score	10 (8-12)	10 (8-12)

Values are medians (IQR) or %

Number of units transfused



4633 units of RBCs

Lower Threshold: 1545

(P < 0.001)

Higher Threshold: 3088

Number of patients transfused



Lower Threshold:

312 patients (64%) received RBC


(P < 0.001)

Higher Threshold:

490 patients (99%) received RBC

Lowest median Hb





Death by 90 days




Lower		Higher	P-value
216 / 502 (43.0)	VS	223 / 496 (45.0)	0.44

Relative Risk 0.94 (95% CI 0.78 – 1.09)

Values are No.(%) and CI denotes confidence interval

Time to death





Use of any life support



	Lower	Higher	Relative Risk (95% CI)	P-value
Day 5	64%	62%	1.04 (0.93 - 1.14)	0.47
Day 14	37%	37%	0.99 (0.81 - 1.19)	0.95
Day 28	16%	20%	0.77 (0.54 - 1.09)	0.14

Ischemic events in the ICU



	Lower		Higher	Relative Risk (95% CI)	P-value
Any event*	7%	VS	8%	0.90 (0.58-1.39) 0.64

*Cerebral, myocardial, intestinal or limb

Clinical implications



Safe using a lower Hb-threshold (7g/dl) to guide RBC transfusion in patients with septic shock resulting in

- Fewer transfusions
- Fewer patients transfused





Guidelines 2007


Hb < 9.8 g/dl

- * Severe ischemic heart disease
- * Early phase of septic shock
- * Acute and severe bleeding


Hb < 7.4 g/dl

* All other patients


RBC per 1000 population




26% reduction RBCs





Posttransfusion Hb 2014



ROTEM & MULTIPLATE








Cardiac surgery

Table 1. The Unadjusted and Adjusted Relative Risk With 95%
Confidence Intervals for Allogeneic Blood Transfusion According to
the Year of Surgery Among Patients Undergoing Elective FirstTime CABG Surgery

Year	Unadjusted RR (95% CI)	Adjusted RR (95% CI)
2004	1.0 (reference)	1.0 (reference)
2008	0.9 (0.7-1.0)	0.7 (0.5-0.9)
2010	0.7 (0.6-0.9)	0.6 (0.5-0.8)

2014 0.4 (0.3-0.6) 0.3 (0.2-0.5)


Abbreviation: Cl, confidence interval.






2011 NCA of Cardiac Surgery


Each line represents the transfusion rate for each component at one hospital





Haemodilation in cardiac surgery

- A low Hb is not the only trigger for RBC
 - Lactate, mixed venous saturation





UPDATE Open Access

Transfusion Indication Threshold Reduction (TITRe2) randomized controlled trial in cardiac surgery: statistical analysis plan

Katie Pike¹, Rachel L Nash¹, Gavin J Murphy², Barnaby C Reeves¹ and Chris A Rogers^{1*}

Abstract

Background: The Transfusion Indication Threshold Reduction (TITRe2) trial is the largest randomized controlled trial to date to compare red blood cell transfusion strategies following cardiac surgery. This update presents the statistical analysis plan, detailing how the study will be analyzed and presented. The statistical analysis plan has been written following recommendations from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, prior to database lock and the final analysis of trial data. Outlined analyses are in line with the Consolidated Standards of Reporting Trials (CONSORT).

Methods and design: The study aims to randomize 2000 patients from 17 UK centres. Patients are randomized to either a restrictive (transfuse if haemoglobin concentration <7.5 g/dl) or liberal (transfuse if haemoglobin concentration <9 g/dl) transfusion strategy. The primary outcome is a binary composite outcome of any serious infectious or ischaemic event in the first 3 months following randomization.


The statistical analysis plan details how non-adherence with the intervention, withdrawals from the study, and the study population will be derived and dealt with in the analysis. The planned analyses of the trial primary and secondary outcome measures are described in detail, including approaches taken to deal with multiple testing, model assumptions not being met and missing data. Details of planned subgroup and sensitivity analyses and pre-specified ancillary analyses are given, along with potential issues that have been identified with such analyses and possible approaches to overcome such issues.

Trial registration: ISRCTN70923932.

Keywords: Cardiac surgery, Red cell, Restrictive, Statistical analysis plan, Transfusion

THANK YOU





"Pull out, Bettyl Pull out! . . . You've hit on artery!"